# Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes

Study · id `cardio:ct-nct06435156` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06435156](<https://clinicaltrials.gov/study/NCT06435156>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06435156

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 320 participants.

## Technical summary

Registry record NCT06435156. Randomized; quadruple masking; primary purpose treatment. Start 2025-01-28 (actual); primary completion 2027-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 320 participants (planned count; ClinicalTrials.gov record NCT06435156, source copy `cardio:ctgov-nct06435156-2026-04-06`, retrieved 2026-10-26)
- Started: 2025-01-28 (actual) (ClinicalTrials.gov record NCT06435156, source copy `cardio:ctgov-nct06435156-2026-04-06`, retrieved 2026-10-26)
- Primary completion: 2027-10-31 (anticipated) (ClinicalTrials.gov record NCT06435156, source copy `cardio:ctgov-nct06435156-2026-04-06`, retrieved 2026-10-26)
- Completion: 2027-10-31 (anticipated) (ClinicalTrials.gov record NCT06435156, source copy `cardio:ctgov-nct06435156-2026-04-06`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT06435156, source copy `cardio:ctgov-nct06435156-2026-04-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06435156-2026-04-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
- Acronym: SOPHIST
- Condition: Type 1 Diabetes
- Condition: Heart Failure
- Intervention (Drug): Sotagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: University of Dundee
- Lead sponsor class: OTHER
- Collaborator: Lexicon Pharmaceuticals
- Collaborator class: INDUSTRY
- Collaborator: Juvenile Diabetes Research Foundation
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Type 1 diabetes (`core:type-1-diabetes`)
- Registry lists this organization as the lead sponsor: University of Dundee (`cardio:org-university-of-dundee`)
- Registry lists this organization as a collaborator: Lexicon Pharmaceuticals (`cardio:org-lexicon-pharmaceuticals`)
- Registry lists this organization as a collaborator: Juvenile Diabetes Research Foundation (`cardio:org-juvenile-diabetes-research-foundation`)

## Provenance

Content hash: 62467e6b262877900217a4e3a8c0f932e5741ce6df1be59fc152af8a67806b34
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
